Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) kicked off on Tuesday, up 4.28% from the previous trading day, before settling in for the closing price of $61.25. Over the past 52 weeks, RYTM has traded in a range of $35.17-$68.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 189.02% over the last five years. While this was happening, its average annual earnings per share was recorded 37.85%. With a float of $58.22 million, this company’s outstanding shares have now reached $63.49 million.
The firm has a total of 283 workers. Let’s measure their productivity. In terms of profitability, gross margin is 89.49%, operating margin of -126.13%, and the pretax margin is -123.16%.
Rhythm Pharmaceuticals Inc (RYTM) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Rhythm Pharmaceuticals Inc is 8.48%, while institutional ownership is 95.84%. The most recent insider transaction that took place on Apr 29 ’25, was worth 457,663. In this transaction Chief Human Resources Officer of this company sold 7,031 shares at a rate of $65.09, taking the stock ownership to the 19,209 shares. Before that another transaction happened on Apr 29 ’25, when Company’s EVP, Head of International sold 6,745 for $65.08, making the entire transaction worth $438,946. This insider now owns 37,655 shares in total.
Rhythm Pharmaceuticals Inc (RYTM) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.62 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 37.85% per share during the next fiscal year.
Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) Trading Performance Indicators
Take a look at Rhythm Pharmaceuticals Inc’s (RYTM) current performance indicators. Last quarter, stock had a quick ratio of 3.13. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 29.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.82, a number that is poised to hit -0.64 in the next quarter and is forecasted to reach -1.42 in one year’s time.
Technical Analysis of Rhythm Pharmaceuticals Inc (RYTM)
Analysing the last 5-days average volume posted by the [Rhythm Pharmaceuticals Inc, RYTM], we can find that recorded value of 0.68 million was better than the volume posted last year of 0.65 million. As of the previous 9 days, the stock’s Stochastic %D was 62.55%. Additionally, its Average True Range was 3.08.
During the past 100 days, Rhythm Pharmaceuticals Inc’s (RYTM) raw stochastic average was set at 89.00%, which indicates a significant increase from 79.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.86% in the past 14 days, which was higher than the 51.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $57.65, while its 200-day Moving Average is $54.64. Now, the first resistance to watch is $64.96. This is followed by the second major resistance level at $66.04. The third major resistance level sits at $68.01. If the price goes on to break the first support level at $61.91, it is likely to go to the next support level at $59.94. Should the price break the second support level, the third support level stands at $58.86.
Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) Key Stats
The company with the Market Capitalisation of 4.06 billion has total of 63,621K Shares Outstanding. Its annual sales at the moment are 130,130 K in contrast with the sum of -260,600 K annual income. Company’s last quarter sales were recorded 32,700 K and last quarter income was -49,500 K.
